The impact of statin use on the efficacy of abiraterone acetate in patients with castration‐resistant prostate cancer
Abstract
Statins compete with DHEAS for influx through the SLCO2B1 transporter, which may prolong time to progression (TTP) on androgen deprivation therapy. Abiraterone acetate (AA) may also undergo SLCO‐mediated transport. Based on preclinical findings showing antagonism, we hypothesized that statins may compete with AA for influx via SLCO2B1 and could negatively impact drug efficacy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2017
- Source ID
- 10.1002/pros.23390
Entities
People
- Abhishek Tripathi
- Benjamin L. Maughan
- Christopher J. Sweeney
- Emmanuel S. Antonarakis
- Gwo‐Shu Mary Lee
- Lauren C Harshman
- Lillian Werner
- Lorelei A. Mucci
- Mari Nakabayashi
- Mark Pomerantz
- Mary‐ellen Taplin
- Philip W. Kantoff
- Rana Mckay
- Xiaodong Wang
Organizations
- Dana–Farber Cancer Institute
- Harvard Medical School
- Harvard T.H. Chan School of Public Health
- Johns Hopkins University
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- Prostate Cancer Foundation
- United States Department of Defense